Vivos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Revenue	15.03	13.8	16.02	16.89	13.07	Upgrade
Revenue Growth (YoY)	8.91%	-13.87%	-5.10%	29.23%	14.68%	Upgrade
Cost of Revenue	6.01	5.53	6.01	4.28	2.65	Upgrade
Gross Profit	9.02	8.27	10.02	12.6	10.41	Upgrade
Selling, General & Admin	19.61	24.85	34.18	31.34	18.4	Upgrade
Research & Development	-	0.1	0.2	-	-	Upgrade
Operating Expenses	20.19	25.57	35.05	32.08	19.12	Upgrade
Operating Income	-11.17	-17.3	-25.03	-19.47	-8.71	Upgrade
Interest Expense	-	-	-	-0.01	-0.1	Upgrade
Interest & Investment Income	-	-	-	-	0.08	Upgrade
Other Non Operating Income (Expenses)	0.04	3.71	-0.1	0.11	-	Upgrade
EBT Excluding Unusual Items	-11.14	-13.58	-25.13	-19.38	-8.73	Upgrade
Asset Writedown	-	-	-	-0.91	-	Upgrade
Other Unusual Items	-	-	1.29	-	-3.33	Upgrade
Pretax Income	-11.14	-13.58	-23.85	-20.29	-12.06	Upgrade
Net Income	-11.14	-13.58	-23.85	-20.29	-12.06	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	-	5.93	Upgrade
Net Income to Common	-11.14	-13.58	-23.85	-20.29	-17.99	Upgrade
Shares Outstanding (Basic)	5	1	1	1	1	Upgrade
Shares Outstanding (Diluted)	5	1	1	1	1	Upgrade
Shares Change (YoY)	311.68%	32.46%	8.39%	65.00%	4.36%	Upgrade
EPS (Basic)	-2.22	-11.14	-25.90	-23.89	-34.94	Upgrade
EPS (Diluted)	-2.22	-11.14	-25.90	-23.89	-34.94	Upgrade
Free Cash Flow	-13.26	-12.8	-20.51	-18.13	-5.8	Upgrade
Free Cash Flow Per Share	-2.64	-10.50	-22.28	-21.35	-11.27	Upgrade
Gross Margin	60.00%	59.93%	62.52%	74.65%	79.70%	Upgrade
Operating Margin	-74.32%	-125.32%	-156.21%	-115.31%	-66.65%	Upgrade
Profit Margin	-74.09%	-98.42%	-148.81%	-120.15%	-137.67%	Upgrade
Free Cash Flow Margin	-88.21%	-92.74%	-128.00%	-107.38%	-44.39%	Upgrade
EBITDA	-10.59	-16.68	-24.36	-18.74	-7.99	Upgrade
EBITDA Margin	-70.45%	-120.82%	-152.03%	-110.97%	-61.16%	Upgrade
D&A For EBITDA	0.58	0.62	0.67	0.73	0.72	Upgrade
EBIT	-11.17	-17.3	-25.03	-19.47	-8.71	Upgrade
EBIT Margin	-74.32%	-125.32%	-156.21%	-115.31%	-66.65%	Upgrade
Revenue as Reported	15.03	13.8	16.02	16.89	13.07	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q